Refuge Biotechnologies
A discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.
Launch date
Employees
Market cap
-
Enterprise valuation
€91—136m (Dealroom.co estimates May 2018.)
Menlo Park California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $8.9m | Series A | |
$25.0m | Series B | ||
| Total Funding | €30.8m | ||
Recent News about Refuge Biotechnologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.